The association between cardiovascular disease (CVD) risk and plasma low density lipoprotein-cholesterol (LDL-c) level is indisputable. Accordingly, all screening and therapeutic guidelines are based on total cholesterol (TC) or LDL-c levels.
Apolipoprotein B & A1